Molecular mechanisms of cell death in neurological diseases

Diane Moujalled 1,2 · Andreas Strasser 1,2 · Jeffrey R. Liddell 3

Received: 23 February 2021 / Revised: 20 May 2021 / Accepted: 24 May 2021 / Published online: 7 June 2021
© Crown 2021. This article is published with open access

Abstract
Tightly orchestrated programmed cell death (PCD) signalling events occur during normal neuronal development in a spatially and temporally restricted manner to establish the neural architecture and shaping the CNS. Abnormalities in PCD signalling cascades, such as apoptosis, necroptosis, pyroptosis, ferroptosis, and cell death associated with autophagy as well as in unprogrammed necrosis can be observed in the pathogenesis of various neurological diseases. These cell deaths can be activated in response to various forms of cellular stress (exerted by intracellular or extracellular stimuli) and inflammatory processes. Aberrant activation of PCD pathways is a common feature in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, resulting in unwanted loss of neuronal cells and function. Conversely, inactivation of PCD is thought to contribute to the development of brain cancers and to impact their response to therapy. For many neurodegenerative diseases and brain cancers current treatment strategies have only modest effect, engendering the need for investigations into the origins of these diseases. With many diseases of the brain displaying aberrations in PCD pathways, it appears that agents that can either inhibit or induce PCD may be critical components of future therapeutic strategies. The development of such therapies will have to be guided by preclinical studies in animal models that faithfully mimic the human disease. In this review, we briefly describe PCD and unprogrammed cell death processes and the roles they play in contributing to neurodegenerative diseases or tumorigenesis in the brain. We also discuss the interplay between distinct cell death signalling cascades and disease pathogenesis and describe pharmacological agents targeting key players in the cell death signalling pathways that have progressed through to clinical trials.

Introduction
Programmed cell death (PCD) is required for normal development and maintenance of tissue homoeostasis, and the elimination of damaged, infected or obsolete cells in multicellular organisms. Seminal discoveries by Kerr et al. in 1972 identified the hallmark ultrastructural features of cells undergoing programmed suicide, where the term ‘apoptosis’ was coined for this form of PCD [1]. These features include cytoplasmic shrinkage, nuclear condensation and fragmentation and the formation of apoptotic bodies that are evident in various tissues under physiological or certain pathological conditions. The family of anti- and pro-apoptotic B cell lymphoma-2 (BCL-2) protein family members has been discovered that regulate this pathway and are comprised of three subgroups based on their structure and function with the presence of conserved regions termed BCL-2 homology (BH) motifs. This includes the anti-apoptotic proteins (BCL-2, BCL-XL, MCL-1, BCL-W and A1/BFL1), the BH3-only proteins (BIM, PUMA, BID, BMF, BAD, HRK, BIK, NOXA), the critical initiators of apoptosis and multi-BH domain proteins (BAX and BAK), the essential effectors of apoptosis that form oligomers that cause mitochondrial outer membrane permeabilisation (MOMP), thereby releasing apoptogenic factors that promote a cascade of caspase (aspartate-specific cysteine proteases) activation [2, 3]. Upon activation, caspases cleave hundreds of cellular substrates,
thereby precipitating the morphological features of apoptosis and demolition of the cell [4–6].

Normal development and tissue homoeostasis in multicellular organisms depend on orchestrated PCD signalling events that are tightly regulated. During embryogenesis, the elimination of cells by PCD is necessary for adequate moulding of certain tissues, for example the sculpting of the digits of vertebrate limbs [7]. The central nervous system (CNS), comprised of the brain and spinal cord, is shaped by PCD where signalling events that are tightly regulated at a temporal and spatial level result in establishment of the neural architecture. In normal neural embryonic and postnatal development, apoptosis is the major form of PCD. Apoptosis can affect distinct cell populations, including neural precursor cells (NPCs), differentiated post-mitotic neurons and glial cells, ensuring the survival only of cells that are of the correct size and shape and have made the proper connections with their axons and neurites [8]. In mouse embryos, neurogenesis occurs as early as E12 when NPCs exit the cell cycle and differentiate into post-mitotic neurons. It was shown that the anti-apoptotic BCL-2 family members myeloid cell leukaemia-1 (MCL-1) and BCL-2-related gene long isomorph (BCL-XL) play critical roles in cell survival during developmental neurogenesis. Neuronal-specific ablation of both proteins resulted in massive apoptotic cell death throughout the entire CNS [9], and even loss of either gene caused fatal defects in the brain [10, 11]. Conversely, the combined absence of BAX, BAK (and their relative BOK) causes an increase of neurons within certain areas of the brain [12], although the impact of this for brain function and behaviour is not known. The critical opposing roles of the pro- and anti-apoptotic members of the BCL-2 family are demonstrated by the observation that the combined loss of one allele of Mcl-1 and one allele of Bclx (Mcl1+/−/Bclx+/− mice) causes severe craniofacial abnormalities and early post-natal death, while additional loss of one allele of Bim (Mcl1+/−/Bclx+/−/Bim+/− mice) prevents these abnormalities completely [13].

While removal of superfluous neuronal cells is vital for normal brain function, aberrant death of distinct neuronal cell populations is a hallmark of pathology associated with neurodegenerative diseases, such as ALS, Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) (reviewed in [14]). Conversely, defects in PCD of neuronal cells or other cell types in the brain is thought to promote development of brain cancers, such as the highly aggressive glioblastoma multiforme [15]. The cell death pathways are associated with distinct morphological and biochemical features (refer to Table 1 for characteristic morphological and biochemical hallmarks, highlighting fundamental differences in the pathways). For example, apoptosis is typically associated with cell shrinkage, while necroptosis involves cell swelling and leakage of cellular contents.

The aetiology of neurodegenerative diseases is multifactorial, being associated with defects in different cellular processes, such as response to oxidative stress, excitotoxicity, mitochondrial dysfunction, protein misfolding (ER

### Table 1 Cell death pathways and associated morphological and biochemical hallmark features.

| Cell death pathway | Morphological features and key biochemical pathway components | References |
|--------------------|-------------------------------------------------------------|-------------|
| Apoptosis          | Nuclear fragmentation, plasma membrane blebbing, cell shrinkage (pyknosis), formation of apoptotic bodies and phagocytosis by neighbouring cells. | [1, 21, 150] |
|                    | Pro-apoptotic BCL-2 family members, caspase activation, cleavage of hundreds of caspase substrates (e.g. ICAD, PARP), PS exposure, ΔΨm dissipation, MOMP and ROS production. | |
| Necroptosis        | Cytoplasmic swelling (oncosis), loss of plasma membrane integrity, swelling of cytoplasmic organelles, RIPK1, RIPK3, MLKL, phosphorylation and ubiquitination of RIPK1, formation of the necroinflammatory complex in the cytosol, phosphorylation and activation of MLKL, the effector of caspases, ROS production and release of DAMPs (and in infected cells also PAMPs). | [57–60] |
| Autophagy          | Accumulation of autophagic vacuoles, vacuolisation of the cytoplasm, no chromatin condensation. atg family of gene encoded proteins, LC3-I to LC3-II conversion and cleavage of p62. | [82, 151] |
| Ferroptosis        | Smaller mitochondria with decreased cristae, increased density and rupture of mitochondrial membrane but with normal nucleus. Iron accumulation, cysteine deprivation and/ or glutathione peroxidase inactivation culminating in lipid peroxidation. | [102] |
| Pyroptosis         | Rupture of the plasma membrane and lack of cell swelling. Inflammatory induced activation of the initiator caspases, caspase-1 and -11, and consequent activation of the effector caspases, caspase-3 and -1. Release of bio-active IL-1β and IL-18 and proteolytic activation of GSDMD, the essential effector of pyroptosis. | [135, 136] |
| Necrosis           | Plasma membrane rupture, swelling of cytoplasmic organelles, lack of inter-nucleosomal DNA fragmentation, depletion of ATP, involvement of calpains and cathepsins, release of DAMPs (and in infected cells also PAMPs). | [139, 152] |

ΔΨm mitochondrial transmembrane potential, MMP mitochondrial membrane potential, LC3 microtubule-associated protein light chain 3, ROS reactive oxygen species, PARP1 poly ADP-ribose polymerase 1, PS phosphatidyl serine, GSDMD gasdermin D, IL-1β interleukin-1β, ATP adenosine triphosphate, calpains calcium-activated non-lysosomal proteases.
Programmed cell death signalling pathways and their roles in neurological diseases

Apoptosis

Apoptosis can be triggered by two distinct pathways: the intrinsic (also called mitochondrial or BCL-2-regulated) pathway and the death receptor (also called extrinsic) pathways [20, 21]. The intrinsic pathway is regulated by the pro- and anti-apoptotic members of the BCL-2 protein family. In healthy cells the anti-apoptotic proteins BCL-2, BCL-XL, MCL-1, BCL-W and A1/BFL1 safeguard cell survival by restraining the essential effectors of cell death BAX and BAK [2]. In response to intracellular stress (e.g. growth factor deprivation, DNA damage, ER stress), the BH3-only proteins (BIM, PUMA, BID, BMF, BAD, HRK, BIK, NOXA), the critical initiators of apoptosis, are transcriptionally or post-transcriptionally upregulated [22]. The BH3-only proteins bind with high affinity to anti-apoptotic BCL-2 proteins, thereby liberating BAX and BAK. Some BH3-only proteins are reported to also activate BAX and BAK directly [2, 3, 23]. Upon activation, BAX and BAK form oligomers that cause MOMP with consequent mitochondrial release of cytochrome c and Smac/DIABLO [21]. These apoptogenic factors promote activation of the caspase cascade, resulting in the cleavage of hundreds of proteins leading to demolition of the cell. The death receptor pathway is activated by ligation of members of the tumour necrosis factor receptor (TNFR) superfamily that have an intracellular death domain by their respective ligands (e.g. FAS activated by FAS ligand) [24]. This promotes the formation of an intracellular death inducing signalling complex, resulting in the activation of caspase-8 and the downstream effector caspases (caspases-3 and -7) (Figs. 1 and 2) [25]. The death receptor pathway can connect to the intrinsic apoptotic pathway through caspase-8-mediated proteolytic activation of the pro-apoptotic BH3-only protein BID (Fig. 1) [24].

Amyotrophic lateral sclerosis (ALS) is a progressive adult-onset form of MND caused by the aberrant death of motor neurons in the cerebral cortex and spinal cord. The resulting motor neuron loss leads to muscle atrophy and weakness, muscle twitches, spasticity and typically death from respiratory failure [26]. Various molecular processes have been associated with this pathology, including oxidative stress, excitotoxicity and mitochondrial dysfunction [27]. Mutations in superoxide dismutase 1 (SOD1) account for ~20% of familial ALS cases [28]. A direct role for SOD1 in regulating the apoptotic machinery was proposed based on reports that on the surface of mitochondria in cells from the spinal cord mutant SOD1 was bound to BCL-2, with the contention that this would inhibit this anti-apoptotic protein [29]. Moreover, changes in the expression of certain BCL-2 family members and caspases have been observed in the spinal cord of transgenic mice expressing mutant SOD1 and from humans affected with ALS [30]. Abnormally reduced levels of anti-apoptotic BCL-2 have been reported in the SOD1G93A mouse model [31, 32] as well as increased expression of the apoptosis effector BAX in spinal cord motor neurons of ALS patients [33]. Abnormally high mRNA levels of the BH3-only protein BIM were found in the spinal cord of post-symptomatic SOD1G85R transgenic mice and, importantly, BIM deficiency extended the lifespan of SOD1G93A mutant mice [34]. The onset of symptoms and terminal illness were also delayed in SOD1G93A mice by administration of the broad spectrum caspase inhibitor zVAD-fmk [35], over-expression of BCL-2 [36] or the absence of the apoptosis effectors BAX and BAK [37].

AD is the leading cause of dementia. Hallmark pathological features of AD include the accumulation of amyloid-β-containing neuritic plaques derived from aggregates produced by sequential cleavages of the amyloid precursor protein (APP), neurofibrillary tangles and dystrophic neurites containing hyperphosphorylated tau [38]. Evidence for a role of apoptosis in neuronal cell death in AD is limited. However, based on immuno-histochemical staining of neurons, it has been proposed that intracellular Aβ can induce apoptosis through p53-dependent transcriptional upregulation of BAX [39, 40] and reductions in BCL-2 and BCL-XL [41]. It was also reported that caspase activation and their cleavage of APP are associated with synapse loss [42–44].

HD is characterised by progressive motor, behavioural and cognitive decline. This is driven by expanded CAG repeats in the HTT gene that encodes huntingtin.
Observations in mouse models of HD include increased levels of pro-apoptotic BIM and BAX in brain lysates at late stages of the disease [45, 46]. Notably, loss of one allele of \textit{Bim} significantly attenuated the accumulation of mHTT (mutant Huntington protein), neuronal death and disease-associated phenotypes [47]. BAX expression in the brain was reported to be maximal in grade 2 and 3 HD brains [48].

Degeneration of the dopaminergic neurons in the substantia nigra is the cause of motor dysfunction in PD that is characterised by a resting tremor as well as abnormal posture and gait. In PD, the predominant mechanism of neuronal death is thought to be via the intrinsic apoptosis pathway in dopaminergic neurons. Inherited forms of PD are associated with mutations in genes associated with mitochondrial function, such as \textit{PRKN}, \textit{LRRK2}, \textit{PINK1} and \textit{PARK7} [49]. The functions of the corresponding proteins may intersect with components of the intrinsic apoptosis pathway given that they are both located on the outer mitochondrial membrane. Indeed, Parkin was shown to suppress apoptosis by ubiquitinating BAK, thereby reducing its oligomerisation and apoptotic activity. PD-associated Parkin mutants had reduced ability to ubiquitinate BAK, suggesting that this would cause an increase in BAK-mediated apoptosis [50]. Caspase inhibitors were shown to be neuroprotective in in vitro models of PD [51]. Examination of brain tissue from PD patients revealed abnormally increased levels of active caspase-3 and BAX [52] as well as significant reductions in BCL-2, which correlated inversely with disease duration and severity [53]. These findings suggest that aberrant activation of the intrinsic apoptotic pathway may contribute to or even be a major driver of neuronal death in PD.

GBM is the most common form of brain cancer in humans with a poor prognosis (5-year survival of only 5%) that is largely due to its invasiveness. GBM cells are resistant to apoptotic stimuli and it is thought that this contributes to the failure of conventional standard of care.

**Fig. 1 Molecular pathways of apoptosis and necroptosis.** Intrinsic apoptosis signalling: in response to growth factor deprivation, DNA damage or oncogene activation, BH3-only pro-apoptotic proteins are induced transcriptionally or post-transcriptionally. The BH3-only proteins bind to and inhibit the anti-apoptotic BCL-2 proteins. This leads to release and activation of the effectors of cell death, BAX and BAK, which then oligomerise and promote mitochondrial outer membrane permeabilisation (MOMP), leading to release of apoptogenic factors, including cytochrome c and Smac/Diablo. This initiates a cascade of caspase activation, cleavage of hundreds of cellular proteins and consequent cell demolition. Death receptor induced (extrinsic) apoptosis signalling: stimulation of death receptors (members of the TNFR family with an intracellular death domain) by their cognate ligands (e.g. stimulation of FAS by FASL) results in adaptor protein (FADD, TRADD) mediated recruitment and activation of the initiator caspase, caspase-8 (in humans also caspase-10), which can then activate downstream effector caspases (caspases-3, -7), resulting in cell demolition (see above). The death receptor induced apoptosis pathway can connect to the intrinsic apoptotic pathway by proteolytic activation of the pro-apoptotic BH3-only protein BID (to generate tBID) by caspase-8. Necroptosis: the best characterised pathway triggering necroptosis is via TNFR1 stimulation. Upon binding of TNF\alpha to TNFR1, cIAPs, RIPK1, TRAFs and TRADD are recruited to the intracellular part of TNFR1, forming the TNFR1 signalling complex I, which activates NFkB and AP1 transcription factors and thereby stimulates cell survival and proliferation. Upon deubiquitination of RIPK1 by CYLD, RIPK1 can bind to TRADD, FADD and caspase-8 forming complex II which can drive caspase-8 mediated apoptosis (see above). In the absence of caspase-8 (genetic ablation or pharmacological inhibition) and the absence or inhibition of cIAP1/2, the necrosome (complex III) is formed where RIPK3 can phosphor-ylate MLKL, promoting its translocation to the plasma membrane where MLKL causes cell lysis, resulting in lytic cell death with release of DAMPs and PAMPs.
treatment in this disease. Human glioblastoma cells were shown to express higher levels of BCL-2 and BCL-XL compared to non-neoplastic glial cells [54]. RNA interference mediated reduction in BCL-2 or BCL-XL was able to kill glioblastoma cells in culture, and this death was caspase dependant [54]. Furthermore, high levels of BCL-XL have been reported to be associated with rapid progression and poor survival of glioblastoma patients and BCL-XL has therefore been proposed as a marker of therapy resistance in this malignancy [55].

**Necroptosis**

Necroptosis is a lytic form of PCD that can drive inflammation. Necroptosis can be induced by the stimulation of TNFR1, TLRs and certain other receptors when the activity of caspase-8 is blocked by pharmacological agents or viral inhibitors [56]. This process involves receptor-interacting serine/threonine protein kinase 1 (RIPK1), which is activated by autophosphorylation [57]. This enables RIPK1 to activate the kinase RIPK3 within a cytoplasmic high molecular weight complex termed the necrosome. RIPK3 then phosphorylates and thereby activates the pseudo-kinase MLKL, the terminal effector of necroptosis that causes lysis of the plasma membrane [58, 59]. This facilitates release of damage-associated molecular patterns (DAMPs), and in the case of infected cells also pathogen-associated molecular patterns (PAMPs) [60], driving an inflammatory response (Fig. 1).

In ALS, necroptosis was reported to be dispensable for motor neuron degeneration, based on the observation that the absence of MLKL did not affect disease onset, progression and survival in SOD1<sup>G93A</sup> mutant mice [61]. In contrast, there was evidence of necroptosis in post-mortem examination of brains from human AD patients, with abundant expression of MLKL compared to brains from healthy controls. Moreover, necroptosis was postulated to exacerbate cognitive deficits in the APP/PS1 mouse model of AD, since treatment with the RIPK1 inhibitor necrostatin-1 reduced neuronal death, attenuated the formation of insoluble Aβ plaques and hyperphosphorylated tau in the cortex and hippocampus and ameliorated cognitive impairment [62, 63]. It is, however, noteworthy that in addition to inducing necroptosis, RIPK1 (and RIPK3) are

---

**Fig. 2 Molecular pathways of ferroptosis and pyroptosis.** Ferroptosis is potentiated by iron which can be imported by TFR1 and DMT1, and BCL-2 and BCL-XL compared to non-neoplastic glial cells [54]. RNA interference mediated reduction in BCL-2 or BCL-XL was able to kill glioblastoma cells in culture, and this death was caspase dependant [54]. Furthermore, high levels of BCL-XL have been reported to be associated with rapid progression and poor survival of glioblastoma patients and BCL-XL has therefore been proposed as a marker of therapy resistance in this malignancy [55].
also involved in activating caspase-8 mediated apoptosis and the production of cytokines and chemokines [64]. It remains unclear inhibition of which of these processes by necrostatin-1 reduced pathology in the APP/PS1 mice. A sub-type of disease-associated microglia has been implicated in promoting the formation of Aβ plaques in AD. A study showed that RIPK1 may promote this behaviour of microglia, thereby triggering inflammation and contributing to pathogenesis [65]. Pharmacological inhibition or genetic ablation of RIPK1 in a mouse model of AD reduced amyloid burden, the levels of inflammatory cytokines and memory deficits [65]. Therefore, RIPK1 is considered a promising target for therapeutic intervention in this disease. In preclinical models of PD, genetic ablation of MLKL or RIPK3 or pharmacological inhibition of RIPK1 exerted neuroprotective effects, with decreased dopaminergic neuron degeneration and improved motor performance. Moreover, phosphorylated (i.e. activated) MLKL was found in post-mortem brain biopsies of human PD patients [66]. In a tissue culture model of PD, treatment with a RIPK1 inhibitor protected iPSC-derived neural cells from PD patients harbouring mutations in the optic atrophy type 1 (OPA1) gene from death and reduced oxidative stress [67].

Evidence of a role of necroptosis in the pathogenesis of HD is limited. One study reported that in the R6/2 transgenic mouse model of HD, in which exon 1 of a mutated human HTT gene is expressed and driven by the human huntingtin promoter [68], treatment with Necrostatin-1 ameliorated symptoms and delayed disease progression, thus identifying a role for RIPK1 in disease progression [69]. However, to date there are no reports on the expression of necroptosis signalling proteins in post-mortem samples from HD patients. Overall, these studies provide evidence that necroptosis may play a role in disease pathogenesis and that inducers of necroptosis, such as RIPK1, may constitute promising ‘druggable’ targets for this neurodegenerative disease.

Stroke constitutes the second leading cause of mortality after ischaemic heart disease. It is caused by insufficient blood flow to the brain, triggering a cascade of pathological responses, including inflammation, ROS production and protein misfolding [70]. In animal models of stroke, such as hypoxia-ischaemia, oxygen-glucose deprivation and collagenase-induced intracerebral haemorrhage, treatment with the RIPK1 inhibitor necrostatin-1 or genetic ablation of proteins critical for necroptosis improved neurological function and attenuated neuronal cell death post brain injury [71–73]. While some studies have indicated that necroptosis plays a role in the pathogenesis of stroke and treatments targeting necroptosis signalling proteins have proved to be neuroprotective in various animal models [70], research into the clinical utility of necroptosis inhibitors in patients is lacking and this area warrants further investigation.

In cancer, there are contradictory reports claiming that necroptosis can either promote or inhibit tumour growth [74], perhaps depending on the type of cancer or whether necroptosis occurs in the malignant cells or in cells of the tumour microenvironment. In head and neck squamous cell carcinoma, RIPK1 expression is downregulated compared to healthy tissues [75], whereas in lung cancer patients and mouse models of lung cancer, RIPK1 expression is markedly elevated in the tumour tissue [76]. In a study of GBM patients, ~30% of tumours exhibited high levels of RIPK1 expression [77] and this correlated with adverse prognosis. Amongst patients with lower grade gliomas, those with higher RIPK3 expression levels had poorer prognosis [78]. In another study, upregulation of MLKL in GBM patients was associated with an unfavourable prognosis [79]. It therefore appears that increased expression of RIPK1, RIPK3 and MLKL may promote tumour growth. This may be linked to reports that necroptosis in cells of the tumour microenvironment drives angiogenesis and inflammation, which can promote cancer cell proliferation and metastasis [80]. With the observations that glioblastoma cells are highly resistant to apoptosis, activation of necroptosis or alternate mechanisms of PCD, may represent promising avenues to explore for cancer therapy. Activators of RIPK1, RIPK3 and MLKL may constitute possible approaches, although the safety of such strategies will need to be established.

**Cell death associated with autophagy**

Autophagy is a highly conserved process for the degradation of macro-molecular structures and even entire organelles that plays critical roles in cellular and tissue homeostasis [81]. This process is important for regulating the cytoplasmic turnover of proteins and entire organelles. A myriad of stimuli can enhance autophagy, including nutrient deprivation, oxidative stress and protein aggregates. In these settings, autophagy reduces cell stress and provides cells with metabolites for repair, survival and growth. Autophagy can be differentiated into three subtypes: macro-autophagy, micro-autophagy and chaperone-mediated autophagy; for a comprehensive review see ref. [82]. Each of these processes is distinct, however, they all converge upon lysosomes for cargo degradation and recycling of intracellular content. Although autophagy is often used to promote cell survival, in certain settings, such as the involution of salivary glands during Drosophila development [83], autophagy is associated with cell killing.

A hallmark of neurodegenerative diseases includes the accumulation of proteinaceous aggregates and ubiquitinated inclusion bodies and they are thought to be involved in the aetiology of these diseases. Aberrant autophagy is a feature of several neurological diseases. In ALS, mutations in
autophagy-related genes, including SQSTM1, OPTN, TBK1, VCP and C9orf72, are associated with familial forms of the disease. The accumulation of autophagosomes in the cytoplasm of spinal cord neurons of ALS patients has been reported [84], as well as an increase in the formation of autophagosomes in SOD1 mutant transgenic mice [85]. In the SOD1[G93A] mouse model of ALS loss of Atg7 accelerated neuromuscular denervation and the onset of hindlimb tremor at the early-symptomatic stage of the disease. However, at late stages of disease, autophagy had an adverse role, where loss of Atg7 slowed disease progression and increased the lifespan of the mice [86].

The accumulation of autophagosomes in neurons is a conspicuous feature of AD in both animal models and patients with observations of increased Aβ generation and accumulation in lysosomes in cells with defects in autophagy. This suggests that the turnover of Aβ is regulated in part by autophagy [87]. Microarray profiling of hippocampal CA1 pyramidal neurons from post-mortem brain tissues from AD patients or controls revealed high expression of autophagy-related genes in early stages of AD. This correlated with increased levels of autophagosome components, increased LC3-positive puncta and defective clearance of autophagic substrates by lysosomes in CA1 pyramidal neurons [88]. Therefore, enhancement of autophagy may be a promising area of investigation for achieving neuroprotective outcomes in AD.

Defects in autophagy are associated with several molecular mechanisms underpinning PD, and several ATG genes were shown to be aberrant in PD [89]. Accordingly, dysregulated autophagy has been identified in brain tissues from PD patients and in PD animal models, suggesting that autophagy plays a role in disease pathogenesis [90].

It is a similar scenario in HD, where accumulation of the huntingtin protein (HTT) is associated with attenuated autophagy [91]. Notably, enhanced autophagy by inhibition of mammalian target of rapamycin signalling was found to enhance the clearance of HTT aggregates and reduced toxicity in Drosophila and mouse models of HD [92]. Paradoxically, ablation of p62, an autophagy receptor, significantly attenuated the formation of nuclear inclusions and motor deficits and prolonged lifespan in a mouse model of HD [93]. These reports exemplify the complexity of targeting autophagy signalling in HD (and possibly other neurological diseases). Thus, substantial additional work is required to arrive at a better understanding of the role of autophagy in HD pathogenesis, so that this knowledge may be used to develop new treatments for HD that are based on manipulating this process.

The role of autophagy in GBM is controversial, with some reports claiming that it suppresses tumour growth whereas others stated that it promotes tumour growth. In U343 glioma cells, autophagy was shown to trigger cell senescence [94] and this also enhanced TMZ-induced senescence in glioma cells [95]. Triggering autophagy was reported to inhibit GBM cell migration and invasive-ness, reversing the epithelial-mesenchymal transition [96]. Conversely, autophagy was also reported to exert positive effects on tumours, increasing their proliferative potential and elevated expression of p62 was correlated with poorer survival in GBM patients [97]. Perturbations in EGFR, PTEN and AKT, which are frequently mutated in GBM, have been reported to impact the regulation of autophagy [98]. Autophagy was also shown to promote survival of GBM cells [99] and to facilitate metastasis [100]. Given the ongoing controversy about the role of autophagy in glioblastoma (and many other cancers for that matter [101]), further interrogation of this pathway is warranted if it should be harnessed for therapeutic intervention in this disease.

**Ferroptosis**

First coined in 2012 [102], ferroptosis refers to a form of iron-dependent necrotic PCD. The final executor in ferroptosis is overwhelming lipid peroxidation causing complete cell failure. Although ferroptosis exhibits many features of what was previously commonly called oxidative stress-induced cell death, there are many aspects that distinguish it as a distinct form of cell death. For instance, ferroptosis is morphologically and functionally distinct from ‘generic’ oxidative stress, such as hydrogen peroxide-induced necrosis [102]. Many molecular components of ferroptosis have been identified, including ACSL4 and LPCAT3 that generate the membrane lipids susceptible to peroxidation [103, 104], and the glutamate-cystine antiporter system xCT required to supply cysteine to the cell. Critical to prevent lipid peroxidation are endogenous mechanisms including glutathione peroxidase 4 (GPX4; [105] and ferroptosis suppressor protein 1 (formerly AIFM2) [106, 107] which use glutathione and ubiquinone, respectively, as reducing substrates, and tetrahydrobiopterin synthesised by GTP cyclohydrolase-1 [108]. Ferroptosis inducers include inhibitors of GPX4 (RSL3, ML210, ML162, FIN56, FINO2), disruption of glutathione synthesis (buthionine sulfoximine), disruption of cysteine supply via inhibition of system xCT (erastin, sorafenib, sulfasalazine, glutamate), iron and iron-disrupting stimuli. Endogenous inhibitors of ferroptosis include glutathione, ubiquinone, vitamin E and selenium. Exogenously applied ferroptosis inhibitors include radical trapping antioxidants (RTAs; ferrostatin-1, liproxstatin-1), inhibition of lipoygenases (in absence of RTA activity, see below) and iron chelators (deferoxamine, deferiprone). The selectivity and potency of RTAs illustrates the unequivocal role of lipid peroxidation in ferroptosis,
Many small molecule inhibitors are redox active and exhibit significant potential to directly inhibit lipid peroxidation [109]. This is problematic when attempting to delineate additional molecular aspects of ferroptosis as such inhibitors may directly inhibit lipid peroxidation independent of interactions with their intended targets. For instance, many lipoxygenase inhibitors are redox active; this includes zileuton, NGDIA, baicalein and PD146176 [109]. Therefore, the use of redox active molecules should be coupled with complementary experimental approaches in order to permit clear interpretation of the findings. Furthermore, when a redox active small molecule exhibits efficacy in a given model of disease, this may be due to inhibition of ferroptosis rather than (or in addition) to their intended action. In light of the increasing evidence for a role of ferroptosis across many conditions, this calls for a re-evaluation of previous studies involving inhibitors that are redox active and inhibit lipid peroxidation.

Specific evidence for a role of ferroptosis in a disease setting is difficult to establish. Almost all neurodegenerative diseases appear to exhibit lipid peroxidation. Likewise, dysregulated iron homoeostasis and diminished glutathione are also common features of neurodegeneration. Perhaps the best evidence comes from the protection afforded by ferroptosis inhibitors in animal models of disease and ultimately in human clinical trials. The canonical RTA ferroptosis inhibitors liproxstatin-1 and ferrostatin-1 have been reported to exhibit efficacy in mouse models of stroke [110], PD [111] and HD slice culture assays [112]. Vitamin E prevents the rapid death of neurons in conditional neuronal Gpx4 knockout mice [113, 114], whereas over-expression of GPX4 protects against intracerebral haemorrhage in rats [115].

Several ferroptosis inhibitors have been assessed in the clinic. In a phase II clinic trial for AD, the iron chelator deferoxamine significantly reduced the rate of cognitive decline in patients [116]. Surprisingly, this study is yet to be replicated after 30 years, although nasal formulations of deferoxamine are showing promise in animal models of AD [117, 118].

More recently, therapeutic strategies targeting iron have focused on the iron chelator deferiprone. Similar to deferoxamine, deferiprone inhibits ferroptosis in vitro, and exhibits efficacy in mouse models of AD, PD and ALS [119–121]. In two phase II trials for PD, deferiprone significantly impacted brain iron levels and either significantly delayed or tended towards slowing progression of symptoms as measured by the UPDRS [117, 121]. A third phase II trial with 140 participants has been completed but is yet to report, while a fourth phase II trial with 372 participants is currently underway. Deferiprone is also currently under clinical investigation for AD and ALS in two large phase II trials.

CuII(atsm) strongly inhibits ferroptosis induced by RSL3 or erastin in neural cells in vitro and in a cell-free lipid peroxidation system [122]. CuIII(atsm) has been extensively investigated (and independently validated) in preclinical animal models and exhibits efficacy in multiple models of ALS, PD and stroke (for review see [123]). Phase I clinical trials for ALS and PD have been completed with encouraging results [124]. A phase II trial with 80 participants is currently ongoing, as well as extension trials for ALS patients from both trials.

Ferroptosis-related gene expression is associated with diagnostic and prognostic factors in glioma [125]. Many anti-cancer drugs appear to target and enhance ferroptosis to kill glioma cells, including withaferin A [126], dihydroartemisinin [127] and ibuprofen [128]. Inducing ferroptosis is thought to enhance effects of ‘traditional’ anti-cancer treatments that trigger other cell death pathways, mostly apoptosis. Feeding glioblastoma bearing mice or rats with iron enhanced the impact of radiation therapy [129, 130]. Moreover, inhibition of xCT by erastin or sulphasalazine potentiated the efficacy of temozolomide [131, 132]. Coatomer Protein Complex, Subunit Zeta 1 (COPZ1) is associated with increased tumour grade. Inhibition of COPZ1 using RNA interference inhibited tumour growth and enhanced survival in mice by increasing intracellular iron by enhancing ferritinophagy [133]. Conversely, glioblastoma cell necrosis that was reported to be driven by neutrophil-triggered ferroptosis was shown to be associated with worsened outcomes [134]. Overall, it appears that the effects of ferroptosis are dependent on many factors. Ferroptosis may kill cancer cells, however, it is not immunosilent raising the issue of what impact this may have on surrounding healthy tissues.

**Pyroptosis**

Pyroptosis is an inflammatory form of PCD involving activation of caspase-1 by inflammasomes. Caspase-1 proteolytically processes pro-IL-1β and pro-IL-18 into the mature inflammatory cytokines IL-1β and IL-18, respectively. Gasdermin D (GSDMD) is the critical executioner of pyroptosis [135]. Caspase-1 cleaves GSDMD and its N-terminal fragment assembles into a plasma membrane pore [136]. This is required for release of bio-active IL-1β and IL-18 as well as other cellular contents, and for the killing of the cell. Historically, pyroptosis was often thought to be a monocyte-specific form of apoptosis, as it exhibits a plasma membrane-blebbing morphology. However, the recent discovery of GSDMD and its pore-formation activity has redefined pyroptosis as a necrotic form of cell death.

Evidence for pyroptosis (accompanied by inflammasome activation and elevated IL-1β and IL-18) has been reported for many neurodegenerative diseases, including AD, PD,
ALS, HD, multiple sclerosis, stroke and traumatic brain injury [137]. Inflammasome activation and pyroptosis have been found in microglia and oligodendrocytes in an animal model of multiple sclerosis, in which pathology was diminished by caspase-1 inhibition [138].

**Necrosis: unregulated cell death**

Necrosis is classically considered an unprogrammed and unregulated cell death process that is characterised by cell swelling, loss of membrane integrity, ‘spillage’ of intracellular contents (DAMPs and PAMPs) into the extracellular environment and dissipation of ion gradients, overall triggering an inflammatory response. Necrosis can occur due to overwhelming stimuli from outside the cell, such as hypoxia, freezing or burning, certain pathogens, physico-chemical stresses (e.g. H$_2$O$_2$), ischaemia-reperfusion and calcium overload [139]. Early events in necrosis include an increase in intracellular Ca$^{2+}$ concentration and generation of reactive oxygen species culminating in events that result in irreversible cell injury. However, unlike necroptosis, necrosis lacks a defined core cellular signalling machinery but Ninj1 has recently been identified as being critical for the rupture of the plasma membrane [140]. Of note, Ninj1 is also critical for the final rupture of the plasma membrane that occurs during necroptosis, pyroptosis and the secondary necrosis that is seen when cells undergoing apoptosis are not engulfed by neighbouring phagocytes. Necrosis is observed in many pathological conditions, including myocardial infarction, stroke, several neurodegenerative diseases and in certain cancers, where factors released from necrotic malignant cells are likely to impact the tumour microenvironment [14, 141].

Since necrosis is an unprogrammed form of cell death, it has been proposed that the necrotic pathology associated with neurological diseases emanates from an interplay of finely tuned programmed necrosis cascades, such as necroptosis, ferroptosis and pyroptosis, and that this is a driver of the neurological diseases (Table 1). It is therefore anticipated that targeting the necrotic PCD pathways may provide novel opportunities for therapeutic intervention which is discussed below. Of note, it remains a distinct possibility that in neurodegenerative diseases at least some aspects of tissue damage, such as the immediate insult from the occlusion of blood vessels in stroke, is actually caused by unregulated (non-programmed) necrosis rather than by any of the programmed necrotic cell death pathways. Such tissue damage may only be alleviated by preventing or reducing the insult causing the pathology in the first place (e.g. increasing perfusion during stroke). Nonetheless, most of the secondary (and possibly tertiary) tissue destruction in neurodegenerative diseases may well be caused by an interplay of apoptosis and the necrotic PCD pathways. Therefore, inhibitors of MLKL, GSDMD and BAX/BAK, the effectors of necroptosis, pyroptosis or apoptosis, respectively, may allow improved outcomes for patients with these diseases [142]. It appears likely that such agents will need to be used in combination due to the ability of cells to engage another PCD process when the one they would normally undergo is blocked [143, 144].

**Therapeutic implications**

The development and study of mouse models (e.g. genetic modifications or treatment with toxic insults) mimicking neurological diseases has led to an understanding of key regulators of the different cell death signalling pathways and their relevance in disease pathogenesis. Even though aberrant apoptotic cell death and expression of key pro-apoptotic proteins are associated with neurodegenerative diseases, targeting apoptosis in vivo has so far proved disappointing. The clinical potential of Minocycline, a second-generation tetracycline was tested in various preclinical mouse models of neurodegenerative diseases, such as ones for ALS, PD and HD. Minocycline blocks the release of cytochrome c from mitochondria, inhibiting this step in apoptosis, and was reported to upregulate the expression of anti-apoptotic BCL-2, also exhibiting anti-inflammatory and antioxidant effects, displaying effective neuroprotective outcomes in preclinical mouse models [145]. However, a recent randomised clinical trial reported that Minocycline was ineffective and failed to delay disease progression in patients with mild AD over a 24 month period [146]. The reason for this is likely that MOMP and loss of ATP production in mitochondria will still occur despite treatment with this agent. Thus, cells exposed to Minocycline would still be ‘functionally dead’.

Pharmacological inhibition or genetic ablation of RIPK1 has produced neuroprotective outcomes in preclinical models of AD, PD and HD. The use of the blood brain barrier-penetrant RIPK1 inhibitor DNL747 was tested in a clinical trial for AD and ALS, even though necroptosis was reported to be dispensable for the latter. DNL747 progressed through phase I trials. However, the trial was then halted in favour of its successor compound, DNL788, which is anticipated to be superior in achieving neuroprotective outcomes [147]. The efficacy of the combination of sodium phenylbuturate and Taurursodiol was recently reported in a randomised, double-blind trial for ALS. Taurursodiol was reported to exert anti-apoptotic properties, inhibiting the translocation of the apoptosis effector BAX to mitochondrial membranes, while sodium phenylbuturate, a histone deacetylase inhibitor can ameliorate toxicity from endoplasmic reticulum stress, thereby promoting cell survival. Measurement of drug impact included examination of...
functional decline, which was reported to be slower compared to the placebo treated control subjects, when assessed over a 24-week period [148]. Bcl2l12, a protein containing a BH2 domain (but none of the other BCL-2 family homology (BH) regions) was reported to drive the development of GBM by interacting with certain members of the BCL-2 protein family and inhibiting the activation of caspases-3 and -7, thereby inhibiting mitochondrial-induced apoptosis [149]. An early phase clinical trial (NCT03020017) in GBM involved

---

**Table 2** Candidate drugs targeting cell death pathways in neurological diseases.

| Cell death pathway | Drug and mechanism of action | Disease | Clinical trial phase (number of participants) and outcome | References and/or clinical trial registration number |
|--------------------|------------------------------|---------|----------------------------------------------------------|-----------------------------------------------------|
| Apoptosis          | Carboplatin, DNA damaging agent triggering apoptosis, Evaluated in combination with Bevacizumab (VEGF inhibitor). Olaparib, PARP inhibitor, sensitizes GBM cells to death receptor-mediated apoptosis induced by TRAIL. These agents all induce apoptosis in malignant cells | GBM | Phase II (122), patients on carboplatin + Bevacizumab; more toxicity without additional clinical benefit compared to placebo. Phased I/IIa (79), Evaluating the therapeutic potential of Olaparib in combination with TMZ and radiation. | ACTRN12610000915055 [153] NCT03212742 [154] |
| Necroptosis        | DNL747; RIPK1 inhibitor      | ALS     | Phase I (15) | NCT03757351 |
|                    |                              | AD      | Phase I (16) | NCT03757325 |
| Autophagy          | Rapamycin; Autophagy enhancer, mTOR inhibitor. Resveratrol; autophagy enhancer | ALS     | Phase II (63) | [155] |
|                    |                              | AD     | Phase III (27), No significant changes in Alzheimer’s Disease Assessment Scale. Phase II (119), no effects of drug treatment on plasma Aβ42, CSF Aβ42, CSF tau, CSF phospho-tau and hippocampal volume. | NCT00678431 [156] NCT01504854 [157] |
|                    |                              | ALS    | Phase III (30), Median survival increased in patients receiving CQ + standard of care treatment. | NCT00224978 [158] |
| Ferroptosis        | Deferiprone; iron chelator   | PD     | Phase II (40) Stabilised brain iron and slowed disease progression (UPDRS). Phase II (22) Deferiprone therapy reduced brain iron content and trended towards improved motor -UPDRS scores and quality of life, but was not significant. Phase II (140) Yet to report. | NCT00943748 [121] NCT01539837 [159] |
|                    |                              | AD     | Phase II (372) Ongoing | NCT02655315 |
|                    |                              | ALS    | Phase II (171) Ongoing | NCT03234686 |
|                    |                              |        | Phase II (23) Decreased iron in spinal cord and motor cortex. Slower disease progression (ALSFRS-R) and weight loss. Phase II (240) Ongoing | NCT02164253 [120] NCT03293069 |
|                    |                              | FRDA   | Phase II 2010 (80) | NCT00530127 |
|                    |                              |        | Phase II 2011 (36) | NCT00897221 |
|                    |                              | ALS    | Phase I (31) Not reported | NCT03204929 |
|                    |                              | PD     | Phase I (50) | NCT02870634 [124] |
|                    |                              |        | Phase I (28) Ongoing | NCT03136809 |
|                    |                              |        | Phase II (80) Ongoing | NCT04082832 |
|                    |                              |        | Phase II (70) Ongoing | NCT04313166 |
|                    |                              | ALS    | Phase I (31) Not reported | NCT03204929 |
|                    |                              | PD     | Phase I (50) | NCT02870634 [124] |
|                    |                              |        | Phase I (28) Ongoing | NCT03136809 |
|                    |                              |        | Phase II (80) Ongoing | NCT04082832 |
|                    |                              |        | Phase II (70) Ongoing | NCT04313166 |
|                    |                              | FRDA   | Phase II 2010 (80) | NCT00530127 |
|                    |                              |        | Phase II 2011 (36) | NCT00897221 |
|                    |                              | ALS    | Phase I (31) Not reported | NCT03204929 |
|                    |                              | PD     | Phase I (50) | NCT02870634 [124] |
|                    |                              |        | Phase I (28) Ongoing | NCT03136809 |
|                    |                              |        | Phase II (80) Ongoing | NCT04082832 |
|                    |                              |        | Phase II (70) Ongoing | NCT04313166 |

**VEGF** vascular endothelial growth factor, **PARP** poly ADP-ribose polymerase, **TRAIL** tumour necrosis factor-related apoptosis-inducing ligand, **mTOR** mammalian target of rapamycin, **CQ** chloroquine, **FRDA** Friedreich’s ataxia, **ACTRN** Australian clinical trial registration number, **NCT** clinical trials.gov identifier, **CSF** cerebrospinal fluid, **UPDRS** Unified Parkinson’s Disease Rating Scale, **ALSFRS-R** Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, **FDA** United States Food and Drug Administration.
evaluating the efficacy of utilising spherical nucleic acid 
gold nanoparticles composed of siRNAs targeting Bcl2l12 
(NU-0129). The nanoparticles can cross the blood brain 
barrier; therefore, it is anticipated that NU-0129 will pene-
trate into the tumour tissue and will be able to inhibit the 
growth of GBM.

Regulators and effectors of the different cell death 
pathways remain attractive therapeutic targets that may 
form the basis for translational work that will hopefully 
lead to improvements for patients with these diseases. 
Given that the aetiology of neurological diseases is 
complex, where multiple cell death mechanisms often in 
conjunction with other cellular processes drive pathology, 
it appears likely that effective therapies will comprise 
inhibitors of more than one cell death programme plus 
inhibitors of additional cellular processes. Table 2 dis-
plays some key targets within cell death pathways which 
have advanced to clinical trials.

Conclusions and perspectives

Many diseases of the brain are associated with defects in 
one or several processes of PCD: either aberrant killing of 
cells that should survive in neurodegenerative disorders or 
aberrant survival of cells that should die during the develop-
ment and therapy of brain cancers. In most neurodegen-
erative diseases it has not yet been unequivocally defined 
whether these defects in cell death are a true cause or at least 
critical contributor to disease or simply a consequence of 
some insult to the tissue where even effective blockade of 
this cell death would not offer improved therapy. In the case 
of brain cancer, as with all types of cancer, effective 
delivery of potent inducers of any type of cell death would 
be expected to cause tumour shrinkage, of course with the 
proviso that it will be safe, i.e. tolerable to vital tissues. We 
contend that much additional research, both basic work in 
animal models and studies with patient material, is needed 
to garner a more detailed understanding of the roles of the 
different processes of cell death in diseases of the brain, so 
that this knowledge can be harnessed to develop truly 
transformative advances in their treatment.

**Facts**

- Neurodegenerative diseases are associated with aberrant 
  neuronal cell death, but the processes leading to such 
  cell death and the mode of cell death still remain 
  unclear.
- Glioblastoma cells are highly resistant to apoptosis; 
  therefore, activation of alternate mechanisms of PCD 
  may represent promising avenues to explore for therapy 
  of this cancer.
- With the brain’s complex cellular and architectural 
  diversity, it is not unreasonable to predict that many 
  forms of cell death may be occurring simultaneously in 
  disease states. Indeed, evidence indicates this is likely 
  the case, with various inhibitors targeting many forms of 
  cell death having beneficial impact in the same 
  disease model.
- Given there are perturbations in more than one PCD 
  signalling pathway and also unprogrammed necrosis in 
  disease pathogenesis, effective therapies will need to 
  comprise inhibitors of more than one type of cell death.

**Open questions**

- Is a defect in a PCD signalling pathway a direct cause or 
  a critical contributor to disease or simply a consequence 
  of some insult to the tissue where even effective 
  blockade of cell death would not offer improved 
  outcome?
- Programmed pathways of lytic cell death are inherently 
  more immunogenic than apoptosis. Will inhibition of 
  lytic PCD pathways be more effective in the treatment of 
  neurodegenerative diseases than blocking apoptosis 
  because the former induces a pro-inflammatory 
  state? Are neurons more susceptible to death in an 
  inflammatory state?
- The ferroptosis PCD pathway is not immune-silent. 
  What impact would this have on surrounding healthy 
  tissues when trying to exploit inducers of ferroptosis for 
  the treatment of brain cancers?

**Author contributions** DM planned the review. All authors contributed 
to the writing and editing of the review.

**Funding** Work by the authors is supported in part by a National 
Health and Medical Research Council (NHMRC) Programme Grant 
#101671 awarded to AS, NHMRC Fellowship #1020363 awarded to 
AS, Leukaemia and Lymphoma Society (LLS) SCOR Grant #7001-13, 
awarded to AS; the estate of Anthony (Toni) Redstone OAM awarded 
to AS and operational infrastructure grants through the Australian 
Government NHMRCs IRIISS and the Victorian State Government 
Operational Infrastructure Support.

**Compliance with ethical standards**

**Conflict of interest** DM and AS are employees of The Walter and 
Eliza Hall Institute, which receives milestone payments and royalties 
from Genentech and AbbVie for the development of ABT-199/vene-
toclax. AS collaborates with Servier on the development of MCL-1-
specific BH3 mimetic drugs for cancer therapy. JRL has no conflict of 
interest.

**Publisher’s note** Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
References

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.
2. Kelly GL, Strasser A. Toward targeting antiapoptotic MCL-1 for cancer therapy. Annu Rev Cancer Biol. 2020;4:299–313.
3. Huang DC, Strasser A. BH3-Only proteins—essential initiators of apoptotic cell death. Cell. 2000;103:839–42.
4. Green DR. The coming decade of cell death research: five riddles. Cell. 2019;177:1094–107.
5. Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175–93.
6. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9:459–70.
7. Haenen G, Vermes I. Apoptosis: programmed cell death in fetal development. Eur J Obstet Gynecol Reprod Biol. 1996;64:129–33.
8. Kuan CY, Roth KA, Flavell RA, Rakic P. Mechanisms of programmed cell death in the developing brain. Trends Neurosci. 2000;23:291–7.
9. Fogarty LC, Flemmer RT, Geizer BA, Licursi M, Karunanithy A, Opferman JT, et al. Mcl-1 and Bcl-x are essential for survival of the developing nervous system. Cell Death Differ. 2019;26:1501–15.
10. Arbour N, Vanderluit JL, Le Grand JN, Jahani-Asl A, Ruzhynsky VA, Cheung EC, et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J Neurosci. 2008;28:6068–78.
11. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science. 1995;267:1506–10.
12. Ke FF, Vaney HK, Cowan AD, Delbridge ARD, Whitehead L, Grabow S, et al. Embryogenesis and adult life in the absence of intrinsic apoptosis effectors BAX, BAK, and BOK. Cell. 2018;173:1217–30 e17.
13. Grabow S, Kueh AJ, Ke F, Vaney HK, Sheikh BN, Dengler MA, et al. Subtle changes in the levels of BCL-2 proteins cause severe craniofacial abnormalities. Cell Rep. 2018;24:3285–95 e4.
14. Gorman AM. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med. 2008;12:2263–80.
15. Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med. 2014;6:1359–70.
16. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918–34.
17. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787–95.
18. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharm Sin. 2009;30:379–87.
19. Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21:1332–40.
20. Green DR. Apoptotic pathways: paper wraps stone blunt scissors. Cell. 2000;102:1–4.
21. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922–33.
22. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 2002;9:505–12.
23. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393–403.
24. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180–92.
25. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798–811.
26. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
27. Moujalled D, White AR. Advances in the development of cell-death-modifying treatments for amyotrophic lateral sclerosis. CNS Drugs. 2016;30:227–43.
28. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:616–30.
29. Pasinelli P, Belford ME, Lennon N, Bacsak BJ, Hyman BT, Trotti D, et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 2004;43:19–30.
30. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39–59.
31. Gonzalez de Aguilar JL, Gordon JW, Rene F, de Tapia M, Lutz-Bucher B, Gaidoed C, et al. Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway. Neurobiol Dis. 2000;7:406–15.
32. Mu X, He J, Anderson DW, Trojanowski JQ, Springer JE. Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann Neurol. 1996;40:379–86.
33. Ekengren T, Grundstrom E, Lindholm D, Aquilonius SM. Upregulation of Bax protein and increased DNA degradation in ALS spinal cord motor neurons. Acta Neurol Scand. 1999;100:317–21.
34. Hetz C, Thienen P, Fisher J, Pasinelli P, Brown RH, Korsmeyer S, et al. The prosapoptotic BCL-2 family member BIM mediates motoneuron loss in a model of amyotrophic lateral sclerosis. Cell Death Differ. 2007;14:1386–9.
35. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000;288:335–9.
36. Vukosavic S, Stefanis L, Jackson-Lewis V, Guegan C, Romero N, Chen C, et al. Delaying caspase activation by Bcl-2: A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2000;20:9119–25.
37. Reyes NA, Fisher JK, Austgen K, VandenBerg S, Huang EJ, Oakes SA. Blocking the mitochondrial apoptotic pathway
preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest. 2010;120:3673–9.
38. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.
39. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer’s disease. FASEB J. 2005;19:255–7.
40. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective caspase activation and caspase-mediated cleavage of APP is associated with amyloid beta-protein-induced synapse loss in Alzheimer’s disease. Cell Rep. 2020;31:107839.
41. Park G, Nhan HS, Tyan SH, Kawakatsu Y, Zhang C, Navarro M, et al. Caspase activation and caspase-mediated cleavage of APP as a possible molecular link between proteasome dysfunction and cell death induced by mutant huntingtin. Eur J Neurosci. 2010;31:1915–25.
42. Lu DC, Soriano S, Bredesen DE, Koo EH. Cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem. 2003;87:733–41.
43. Zhang Y, Ona VO, Li M, Drozda M, Dubois-Dauphin M, Adamio L. Alternative, non-secretase processing of Alzheimer’s beta-amyloid precursor protein during apoptosis by caspase-6 and -8. J Biol Chem. 1999;274:21011–6.
44. Vis JC, Schipper E, de Boer-van Huizen RT, Verbeek MM, de Waal RM, Wesseling P, et al. Expression pattern of apoptosis-related markers in Huntington’s disease models. Cell Death Dis. 2011;2:e115.
45. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2:a008888.
46. Bernardini JP, Brouwer JM, Tan IK, Sandow JJ, Huang S, Stafford CA, et al. Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy. EMBO J. 2019;38:e99916.
47. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet. 2007;16:1319–26.
48. Tran NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp Neurol. 2000;166:29–43.
49. Blundell F, Mangiaigalli A, Cosentino M, Marino F, Samuele A, Rasini E, et al. Peripheral markers of apoptosis in Parkinson’s disease: the effect of dopaminergic drugs. Am N Y Acad Sci. 2005;1049:321–8.
50. Iannielli A, Bido S, Polladori L, Segnali A, Cancellieri C, Maresca A, et al. Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in Parkinson’s disease models. Cell Rep. 2018;22:2066–79.
51. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493–506.
52. Zhu S, Zhang Y, Bai G, Li H. Necrostatin-1 ameliorates intracerebral hemorrhage-induced brain injury in mice through inhibiting RIP1/RIP3 pathway. Neurochem Res. 2015;40:643–50.
53. Sekerdag E, Solorgliu I, Gursoy-Ozdemir Y. Cell death mechanisms in stroke and novel molecular and cellular treatment options. Curr Neuropsychopharmacol. 2018;16:1396–415.
54. Lu DC, Soriano S, Bredesen DE, Koo EH. Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS. Cell Death Differ. 2020;27:1728–39.
55. Onate M, Catenaccio A, Piras IS, Ferreira E, Huettelman MJ, Liang WS, et al. Necroptosis activation in Alzheimer’s disease. Nat Neurosci. 2017;20:1236–46.
56. Caccamo A, Branca C, Follador I, Segnali A, Cancellieri C, Maresca A, et al. Necroptosis mediates axonal degeneration in a model of Parkinson disease. Cell Death Differ. 2020;27:1169–85.
57. Iannelli A, Bido S, Polladori L, Segnali A, Cancellieri C, Maresca A, et al. Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in Parkinson’s disease models. Cell Rep. 2018;22:2066–79.
58. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493–506.
59. Zhu S, Zhang Y, Bai G, Li H. Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington’s disease. Cell Death Dis. 2011;2:e115.
D. Moujalled et al.

74. Qin X, Ma D, Tan YX, Wang HY, Cai Z. The role of necroptosis in cancer: a double-edged sword? Biochim Biophys Acta Rev Cancer. 2019;1871:259–66.

75. McCormick KD, Ghosh A, Trivedi S, Wang L, Coyne CB, Ferris RL, et al. Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. Carcinogenesis. 2016;37:522–9.

76. Wang Q, Chen W, Xu X, Li B, He W, Padilla MT, et al. RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. Carcinogenesis. 2013;34:2119–28.

77. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappab activation and confers a worse prognosis in glioblastoma. Cancer Res. 2009;69:2809–16.

78. Vergara GA, Eugenio GC, Malheiro SMF, Victor EDS, Weinitz R. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping. J Neurooncol. 2020;147:587–94.

79. Dong Y, Sun Y, Huang Y, Dwarakanath B, Kong L, Lu JJ. Unregulated necroptosis-pathway-associated genes are unfavorable prognostic markers in low-grade glioma and glioblastoma multiforme. Transl Cancer Res. 2019;8:821–7.

80. Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18:100.

81. Ohsumi Y. Historical landmarks of autophagy research. Cell Res. 2014;24:9–23.

82. Yang Y, Klionsky DJ. Autophagy and disease: unanswered questions. Cell Death Differ. 2020;27:858–71.

83. Doherty J, Baehrecke EH. Life, death and autophagy. Nat Cell Biol. 2012;14:253–6.

84. Ohsumi Y. Historical landmarks of autophagy research. Cell Res. 2014;24:9–23.

85. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappab activation and confers a worse prognosis in glioblastoma. Cancer Res. 2009;69:2809–16.

86. Vergara GA, Eugenio GC, Malheiro SMF, Victor EDS, Weinitz R. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping. J Neurooncol. 2020;147:587–94.

87. Dong Y, Sun Y, Huang Y, Dwarakanath B, Kong L, Lu JJ. Unregulated necroptosis-pathway-associated genes are unfavorable prognostic markers in low-grade glioma and glioblastoma multiforme. Transl Cancer Res. 2019;8:821–7.

88. Sasaki S. Autophagy in spinal cord motor neurons in sporadic Huntington disease. Mol Genet. 2004;36:585–95.
112. Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014;136:4551–6.

113. Hambright WS, Fonseca RS, Chen L, Na R, Ran Q. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 2017;12:8–17.

114. Chen L, Hambright WS, Na R, Ran Q. Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J Biol Chem. 2015; 290:28097–106.

115. Zhang Z, Wu Y, Yuan S, Zhang P, Zhang J, Li H, et al. Glutathione peroxidase 4 participates in secondary brain injury through mediating ferroptosis in a rat model of intracerebral hemorrhage. Brain Res. 2018;1701:112–25.

116. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet. 1991;337:1304–8.

117. Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging. 2013;34:562–75.

118. Zhang Y, He ML. Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposition in APP/PS1 mice. Brain Res. 2017;1677:86–92.

119. Hao SS, Portbury SD, Lago L, Bush AI, Adlard PA. The iron chelator deferriprone improves the phenotype in a mouse model of tauopathy. J Alzheimers Dis. 2020;78:1783.

120. Moreau C, Danier V, Devedjian JC, Grolez G, Timmerman K, Laloux C, et al. Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? Antioxid Redox Signal. 2018;29:724–9.

121. Devos D, Moreau C, Devedjian JC, Kluzo J, Petrutta M, Laloux C, et al. Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal. 2014;21:195–210.

122. Southon A, Szotak K, Acevedo KM, Dent KA, Volitakis I, Belaidi AA, et al. Cu(II) (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. Br J Pharmacol. 2020;177:656–67.

123. Niokeresht S, Hilton JBW, Kysienia K, Liddell JR, Crouch PJ. Copper-ATSM as a treatment for ALS: support from mutant SOD1 models and beyond. Life (Basel). 2020;10:27.

124. Rowe D, Mathers S, Smith G, Windebank E, Rogers M-L, Southon A, Szostak K, Acevedo KM, Dent KA, Volitakis I, Belaidi AA, et al. Flexible usage and interconnectivity of diverse cell death programmes and their physiological implications. J Exp Med. 2019;216:1474–86.

125. Hoeffer M, Deng Y, Whitney P, Salvamoser R, Engel S, Kueh AJ, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11:5424.

126. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. cell death and its physiological implications. J Exp Med. 2019;216:1474–86.

127. Yi R, Wang H, Deng C, Wang X, Yao L, Niu W, et al. Dihydroxartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition. Biosev Res. 2020;40:BSR20193314.

128. Gao X, Guo N, Xu H, Pan T, Lei H, Yan A, et al. Ibuprofen induces ferroptosis of glioblastoma cells via downregulation of nuclear factor erythroid 2-related factor 2 and signaling pathway. Anticancer Drugs. 2020;31:27–34.

129. Ivanov SD, Semenov AL, Mikhelson VM, Kovan’ko EG, Iamshanov VA. Effects of iron ion additional introduction in radiation therapy of tumor-bearing animals. Radiat Biol Radioecol. 2013;53:296–303.

130. Ivanov SD, Semenov AL, Kovan’ko EG, Yamasanov VA. Effects of iron ions and iron chelation on the efficiency of experimental radiotherapy of animals with gliomas. Bull Exp Biol Med. 2015;158:800–3.

131. Sehn T, Rauh M, Wiendieck M, Buchfelder M, Eyupoglu IY, Savaskan NE. Temozolomide toxicity operates in a cX7/SLC7a11 dependent manner and is fostered by ferroptosis. Oncotarget. 2016;7:74630–47.

132. Sehn T, Fan Z, Ghochchi A, Rauh M, Engelhorn T, Minakaki G, et al. Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. Oncotarget. 2016;7:36021–33.

133. Zhang Y, Kong Y, Ma Y, Ni S, Wikerholmen T, Xi K, et al. Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines. Oncogene. 2021;40:1425–39.

134. Hambright WS, Fonseca RS, Chen L, Na R, Ran Q. Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J Biol Chem. 2015; 290:28097–106.

135. Zhang Z, Wu Y, Yuan S, Zhang P, Zhang J, Li H, et al. Glutathione peroxidase 4 participates in secondary brain injury through mediating ferroptosis in a rat model of intracerebral hemorrhage. Brain Res. 2018;1701:112–25.

136. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet. 1991;337:1304–8.

137. Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging. 2013;34:562–75.

138. Zhang Y, He ML. Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposition in APP/PS1 mice. Brain Res. 2017;1677:86–92.

139. Hao SS, Portbury SD, Lago L, Bush AI, Adlard PA. The iron chelator deferriprone improves the phenotype in a mouse model of tauopathy. J Alzheimers Dis. 2020;78:1783.

140. Moreau C, Danier V, Devedjian JC, Grolez G, Timmerman K, Laloux C, et al. Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? Antioxid Redox Signal. 2018;29:724–9.

141. Devos D, Moreau C, Devedjian JC, Kluzo J, Petrutta M, Laloux C, et al. Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal. 2014;21:195–210.

142. Southon A, Szotak K, Acevedo KM, Dent KA, Volitakis I, Belaidi AA, et al. Cu(II) (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. Br J Pharmacol. 2020;177:656–67.

143. Niokeresht S, Hilton JBW, Kysienia K, Liddell JR, Crouch PJ. Copper-ATSM as a treatment for ALS: support from mutant SOD1 models and beyond. Life (Basel). 2020;10:27.

144. Rowe D, Mathers S, Smith G, Windebank E, Rogers M-L, Southon A, Szostak K, Acevedo KM, Dent KA, Volitakis I, Belaidi AA, et al. Flexible usage and interconnectivity of diverse cell death programmes and their physiological implications. J Exp Med. 2019;216:1474–86.

145. Hoeffer M, Deng Y, Whitney P, Salvamoser R, Engel S, Kueh AJ, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11:5424.

146. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. cell death and its physiological implications. J Exp Med. 2019;216:1474–86.

147. Yi R, Wang H, Deng C, Wang X, Yao L, Niu W, et al. Dihydroxartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition. Biosev Res. 2020;40:BSR20193314.

148. Gao X, Guo N, Xu H, Pan T, Lei H, Yan A, et al. Ibuprofen induces ferroptosis of glioblastoma cells via downregulation of nuclear factor erythroid 2-related factor 2 and signaling pathway. Anticancer Drugs. 2020;31:27–34.

149. Ivanov SD, Semenov AL, Mikhelson VM, Kovan’ko EG, Iamshanov VA. Effects of iron ion additional introduction in radiation therapy of tumor-bearing animals. Radiat Biol Radioecol. 2013;53:296–303.

150. Ivanov SD, Semenov AL, Kovan’ko EG, Yamasanov VA. Effects of iron ions and iron chelation on the efficiency of experimental radiotherapy of animals with gliomas. Bull Exp Biol Med. 2015;158:800–3.
152. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3–11.

153. Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol. 2015;17:1504–13.

154. Lesueur P, Lequesne J, Grellard JM, Dugue A, Coquan E, Brachet PE, et al. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer. 2019;19:198.

155. Mandrioli J, D’Amico R, Zucchi E, Gessani A, Fini N, Fasano A, et al. Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore). 2018;97:e11119.

156. Zhu CW, Grossman H, Neugroschl J, Parker S, Burden A, Luo X, et al. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer’s disease: a pilot study. Alzheimers Dement. 2018;4:609–16.

157. Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85:1383–91.

158. Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144:337–43.

159. Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blind placebo controlled clinical trial in Parkinson’s disease. Sci Rep. 2017;7:1398.